Literature DB >> 33723793

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin.

David Busse1,2, André Schaeftlein3, Alexander Solms4,5, Luis Ilia1, Robin Michelet1, Markus Zeitlinger6, Wilhelm Huisinga4, Charlotte Kloft7.   

Abstract

PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response.
METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches.
RESULTS: Individual AUCISF estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%-143%CVPK, integral-CA = 26.4%-72.6%CVPK) from recovery-related variability only in integral-CA (41.0%-50.3%CVrecovery). This also led to increased variability of AUCplasma for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values.
CONCLUSIONS: Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making.

Entities:  

Keywords:  levofloxacin; microdialysis; noncompartmental analysis; nonlinear mixed-effects modelling; probability of target-attainment

Mesh:

Substances:

Year:  2021        PMID: 33723793      PMCID: PMC7994214          DOI: 10.1007/s11095-021-02994-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  44 in total

1.  Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen.

Authors:  I Tegeder; J Lötsch; M Kinzig-Schippers; F Sörgel; G R Kelm; S T Meller; G Geisslinger
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

Review 2.  Quantitative in vivo microdialysis in pharmacokinetic studies: some reminders.

Authors:  M J Cano-Cebrián; T Zornoza; A Polache; L Granero
Journal:  Curr Drug Metab       Date:  2005-04       Impact factor: 3.731

3.  A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung.

Authors:  Markus A Zeitlinger; Friederike Traunmüller; Aiman Abrahim; Michael R Müller; Zeynep Erdogan; Markus Müller; Christian Joukhadar
Journal:  Int J Antimicrob Agents       Date:  2007-01       Impact factor: 5.283

4.  A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.

Authors:  Sami Ullah; Peter Matzneller; Markus Zeitlinger; Uwe Fuhr; Max Taubert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-06       Impact factor: 3.000

5.  Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Authors:  P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial.

Authors:  Christoph Dorn; David Petroff; Nancy Neumann; Alexander Kratzer; Nahed El-Najjar; Arne Dietrich; Charlotte Kloft; Markus Zeitlinger; Martin G Kees; Frieder Kees; Hermann Wrigge; Philipp Simon
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

7.  Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis.

Authors:  M A Zeitlinger; B M Erovic; R Sauermann; A Georgopoulos; M Müller; C Joukhadar
Journal:  J Antimicrob Chemother       Date:  2005-08-24       Impact factor: 5.790

8.  Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.

Authors:  Margreke J E Brill; Aletta P I Houwink; Stephan Schmidt; Eric P A Van Dongen; Eric J Hazebroek; Bert van Ramshorst; Vera H Deneer; Johan W Mouton; Catherijne A J Knibbe
Journal:  J Antimicrob Chemother       Date:  2013-11-08       Impact factor: 5.790

9.  Tissue pharmacokinetics of levofloxacin in human soft tissue infections.

Authors:  Romuald Bellmann; Gerald Kuchling; Pejman Dehghanyar; Markus Zeitlinger; Erich Minar; Bernhard X Mayer; Markus Müller; Christian Joukhadar
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

10.  Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.

Authors:  F Scaglione; J W Mouton; R Mattina; F Fraschini
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more
  5 in total

1.  Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide.

Authors:  Josefine Schulz; Robin Michelet; Markus Zeitlinger; Gerd Mikus; Charlotte Kloft
Journal:  Pharm Res       Date:  2022-09-28       Impact factor: 4.580

2.  High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients.

Authors:  D Busse; P Simon; D Petroff; N El-Najjar; L Schmitt; D Bindellini; A Dietrich; M Zeitlinger; W Huisinga; R Michelet; H Wrigge; C Kloft
Journal:  Antimicrob Agents Chemother       Date:  2022-05-23       Impact factor: 5.938

3.  Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.

Authors:  David Busse; Philipp Simon; Lisa Schmitt; David Petroff; Christoph Dorn; Arne Dietrich; Markus Zeitlinger; Wilhelm Huisinga; Robin Michelet; Hermann Wrigge; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2021-12-11       Impact factor: 5.577

4.  Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure-Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli.

Authors:  Johanna Seeger; Sebastian Guenther; Katharina Schaufler; Stefan E Heiden; Robin Michelet; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2021-05-21

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.

Authors:  Matthew William McCarthy
Journal:  Clin Pharmacokinet       Date:  2021-07-13       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.